10.3390/biomedicines2040247 [DOI] [PMC free article] [PubMed] [Google Scholar] Gallo S., Sala V., Gatti S., Crepaldi T
Still, a few risks deserve attention: Absolute contraindications: Wilson's disease or any other copper metabolism disorder, active cancer (because of GHK-Cu's pro-angiogenic activity), pregnancy, and breastfeeding
It helps blunt the inflammatory response
3) and an improvement in quality of life.40 Pending the results of cardiovascular safety studies in obesity (SURMOUNT MMO) and diabetes (SURPASS-CVOT), TZP has demonstrated in the SURMOUNT-1 trial a reduction in the predicted 10-year cardiovascular risk in patients with obesity and an initially moderate-to-high risk of cardiovascular disease.43 TZP treatment effectively reduces the apnoeahypopnoea index by up to 23 events per hour, as well as blood pressure, C-reactive protein, and symptoms related to poor sleep quality (as assessed by PROMIS Sleep scales), likely due to weight loss and improvement in adipocyte dysfunction.44 Moreover, TZP induces remission of histologically confirmed metabolic dysfunction-associated steatohepatitis (MASH) in a dose-dependent manner (4462% of cases, depending on the dose) and leads to improvement of at least one stage of liver fibrosis in 5155% of caseshigher than that observed with placebo45 (Fig
In the TRIUMPH-1 trial, the 4 mg dose had a lower discontinuation rate due to adverse events than even placebo, suggesting that lower doses are well-tolerated
